Please login to the form below

major depressive disorder

This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.

treatment for psychotic symptoms in other diseases, including schizophrenia, dementia and major depressive disorder.

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

SUD). It then followed this up with the approval in December 2018, of reSET-O, for the treatment of Opioid Use Disorder, which it co-markets with Novartis subsidiary Sandoz.. ... to develop a similar CBT-based app for the treatment of major depressive
Sage’s postpartum depression treatment Zulresso gains US approval

Brody says the ability to rapidly reduce symptoms in the disorder was an “exciting milestone in women’s mental health.”. ... Analysts forecast sales in excess of $1bn for the compound if it can gain approval in PPD and in the larger patient group
Depression drug failure adds to Allergan's woes

Axe hangs over remaining monotherapy and suicidality trials. Allergan’s novel treatment for major depressive disorder (MDD) rapastinel has failed in three pivotal phase 3 studies. ... The misfiring of rapastinel is a major blow for the company’s most
J&J’s Spravato breaks depression drought at FDA

major depressive disorder (MDD) who haven’t seen any improvement in mood after trying two different drugs previously.
Sage raises $575m ahead of FDA review date for Zulresso

It also has an FDA breakthrough designation for this indication. The follow-up is also being developed in a phase 3 programme as a short oral course for major depressive disorder, ... It is also in earlier-stage studies for MDD plus insomnia as a

More from news
Approximately 6 fully matching, plus 55 partially matching documents found.

Leo has its eyes on the prize

condition and the promise of major therapeutic breakthroughs. ... major depressive disorder and iron-deficiency anaemia.
Pharma deals continue to slide

74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Add my company

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...